Drug Profile
Research programme: antiepileptic therapies - Epilepsy Foundation/Intellimedix/Pfizer
Latest Information Update: 28 Aug 2018
Price :
$50
*
At a glance
- Originator Epilepsy Foundation; Intellimedix; Pfizer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for research development in Epilepsy in USA
- 08 Jul 2014 Early research in Epilepsy in USA (unspecified route)